Rolvedon neutropenia
Search results
Scope
Date
~
-
Bio & PharmaHanmi's Rolvedon set to post $10 mn in Q4 net sales in US
South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...
Feb 02, 2023 (Gmt+09:00)
-
Bio & PharmaHanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum
South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has ob...
Sep 13, 2022 (Gmt+09:00)
-
Bio & PharmaKorea Hanmi to launch blockbuster hypertension drug in China
South Korea’s Hanmi Pharmaceutical Co. is set to launch its blockbuster high blood pressure drug Amosartan in China, the world’s largest...
Mar 11, 2022 (Gmt+09:00)
language
1
Latest News
- 1 Korea’s top cinema chains seek merger to counter box office slump
- 2 S.Korea’s GEPS to commit $143 million to foreign mid-cap buyout funds
- 3 CJ CheilJedang to open $72 mn dumpling plant in Japan
- 4 LG Electronics breaks ground on $600 million home appliance plant in India
- 5 KakaoBank posts record Q1 profit, eyes Thai expansion after Indonesia
